Research programme: Anti-bacterial therapeutics - Sumitomo Dainippon Pharma

Drug Profile

Research programme: Anti-bacterial therapeutics - Sumitomo Dainippon Pharma

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer Sumitomo Dainippon Pharma
  • Class Diterpenes
  • Mechanism of Action Enzyme inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Japan
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
  • 14 Aug 2014 Questcor Pharmaceuticals has been acquired by Mallinckrodt plc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top